Rigel ( (RIGL)) has provided an announcement. On December 7, 2025, Rigel Pharmaceuticals announced updated data from its ongoing Phase 1b study of R289, an oral prodrug, in patients with relapsed or ...

Rigel Pharmaceuticals stock has seen its fair value estimate tick up to $49.60 from $46.60, underpinned by stronger long term revenue growth assumptions of about 9.8% versus 8.8% previously. At the ...

Don't miss 'The Curse of Rigel ' Expansion Launch Trailer for Wartales, an open-world turn-based strategy RPG developed by Shiro Games. Players will enforce the King's will to venture into the County ...

SOUTH SAN FRANCISCO, Calif., Dec. 7, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today ...

R289 continues to be generally well tolerated and at doses of ≥500 mg QD preliminary efficacy was observed in elderly, heavily pre-treated lower-risk MDS patients RBC-TI was achieved by 33% (6/18) of ...

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." ...

Almost a year to the day after Roche pulled out a partnership on its underperforming cancer therapy Gavreto, Blueprint Medicines has sold US commercial rights to the drug to Rigel Pharma in a deal ...

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The ...

Haunting trails of bravery and mental fortitude await sellswords in the shadow-ecliped Sylve Forest, located deep within the cursed County of Rigel. Strange disappearances, vicious murders, and ...